2023 Rocky Mountain Huntington's Disease Family Education Day, October 21

Join us on Saturday, October 21, for the 2023 Rocky Mountain Huntington's Disease Family Education Day at Bethany Lutheran Church, 4500 E Hampden Avenue in Cherry Hills Village. Hear presentations on HD research, patient care and more. Doors open at 8:30 am and admission is free. And if you can’t make it in person, you can experience the entire symposium online on Facebook and the Movement Disorders Foundation website on Saturday, November 11.

Click here for up-to-date program and registration information. Presented by Movement Disorders Foundation and the HDSA Centers of Excellence at the Rocky Mountain and University of Colorado Movement Disorders Centers.

RISE-PD full data highlight IPX203’s impact as promising Parkinson treatment

Months after the FDA issued Amneal Pharmaceuticals a complete response letter for its investigational Parkinson's disease agent IPX203, investigators have published the full dataset of RISE-PD, the phase 3, double-blind study used to support the agent’s application.

All told, patients treated with the extended-release carbidopa-levodopa (CD/LD) solution showed more hours of good ON time per day than those on immediate-release (IR) CD/LD. Patients on IPX203, in fact, received less doses than those on traditional IR CD/LD and demonstrated 0.53 more hours of good ON time per day than IR CD/LD. Click here to learn more.

Medications for chronic diseases can impair thermoregulation, especially in hot weather

Medications to treat various chronic diseases may hinder the body’s ability to lose heat and regulate its core temperature to optimal levels. The loss of effective thermoregulation has implications for elderly people receiving treatment for illnesses like cancer, cardiovascular, Parkinson’s disease/dementia and diabetes, particularly during hot weather, according to a review by a team of scientists from various institutions in Singapore.

The findings show that medications used to treat common chronic conditions, like blood thinners, blood pressure drugs, Parkinson’s disease/Alzheimer’s medications, and some chemotherapy drugs, can make it harder for the human body to handle hot weather by reducing its ability to sweat or increase blood flow to the skin. Click here to learn more.

FDA approves expanded indication of daxibotulinumtoxinA to treat cervical dystonia

The FDA has approved Revance’s daxibotulinumtoxinA-Ianm (Daxxify) for the treatment of cervical dystonia in adults, expanding its previous label as a therapy for the temporary improvement of moderate to severe glabellar lines. It becomes the first and only peptide-formulated, long-lasting neuromodulator for patients with cervical dystonia.

In a phase 3 study and open-label extension, patients treated with daxibotulinumtoxinA showed significant improvements in their condition. "Daxxify's differentiated efficacy, duration, and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population," according to Mark J. Foley, chief executive officer of Revance. Click here to learn more.

Emerging therapies in movement disorders and chronic care management for Parkinson's disease

The field of movement disorders has slowly been making progress in the approval of new therapies in comparison with other subspecialties in neurology, leaving patients and clinicians in a state of longing for more effective treatments. The implications of this slow-moving progress and the need for more innovative solutions have ignited a sense of urgency among patients and in the clinical community. 

Safia Abdillahi, ACNP-BC, DNP, is a nurse practitioner in the movement disorder division of Georgetown University Hospital. Click here to hear Abdillahi's interview with NeurologyLive® and her thoughts on some of the challenges that clinicians face in providing comprehensive care for patients with PD.